1. Effectiveness of an Evidence-Based Induction Therapy Protocol Revision in Adult Kidney Transplant Recipients
- Author
-
John W. McGillicuddy, Kimberly M. Boyle, Caitlin R. Mardis, Kenneth D. Chavin, James N. Fleming, Nicole A. Pilch, Kelly L. Covert, Prabhakar K. Baliga, D.J. Taber, Holly B. Meadows, Carmelina Staino, and Jillian P. Casale
- Subjects
Adult ,Graft Rejection ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,030230 surgery ,law.invention ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Clinical Protocols ,law ,Internal medicine ,Medicine ,Humans ,Pharmacology (medical) ,Intensive care medicine ,Kidney transplantation ,Retrospective Studies ,Protocol (science) ,Evidence-Based Medicine ,business.industry ,Induction chemotherapy ,Retrospective cohort study ,Immunosuppression ,Evidence-based medicine ,Induction Chemotherapy ,Middle Aged ,medicine.disease ,Kidney Transplantation ,Transplant Recipients ,Treatment Outcome ,030211 gastroenterology & hepatology ,Female ,business ,Immunosuppressive Agents ,Cohort study ,Follow-Up Studies - Abstract
tudy objective Induction immunosuppression significantly improves graft outcomes following kidney transplantation, but protocols vary among transplant centers due to the lack of data identifying an optimal induction agent. The objective of this study was to assess the effectiveness of an evidence-based protocol change in induction therapy in adult kidney transplant recipients. Design Retrospective cohort study. Setting Large tertiary care academic medical center. Patients A total of 349 patients transplanted between August 2011 and December 2013 were included in the study. A protocol revision in 2012 reserved the use of lymphocyte-depleting induction therapy to a select group of traditionally high-risk patients based on findings of previous randomized, controlled trial performed at this center. Measurements and Main Results The primary outcome was biopsy proven acute rejection and graft loss. The use of non-depleting induction therapy increased significantly after the protocol revision, with no significant differences in rejection or infection rates identified between protocols. When comparing graft survival between the protocol cohorts, there was no significant difference. A cost-minimization analysis indicated that the revised protocol was associated with considerable medication cost savings. Conclusion A protocol targeting the use of lymphocyte-depleting induction to a select group of high-risk recipients appears to have equivalent efficacy and safety and is less costly compared with a more traditional induction protocol. This article is protected by copyright. All rights reserved.
- Published
- 2017